Mortality Advantage With Pimavanserin in Parkinson's Psychosis? - Medscape

Use of pimavanserin was associated with 35% lower mortality for patients with Parkinson's disease–related psychosis compared with atypical antipsychotics, a large new real-world analysis shows.

Pimavanserin may convey a mortality advantage over other treatments for older adults with Parkinson's disease (PD) psychosis, new research suggests. In a real-world analysis of more than 21,000 pati… [+3825 chars]

full article...